Quick Dispatch:
Your tirzepatide cvot Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cvot Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes ships.
Need Help?
Questions about tirzepatide cvot Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cvot Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes in your area.
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
24.26
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
23.89
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
24.66
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
23.15
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
24.98
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx
26.78
Overview of key tirzepatide clinical trials and their cardiovascular
22.98
